A share price of NewAmsterdam Pharma Company NV [NAMS] is currently trading at $19.71, up 10.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NAMS shares have gain 3.09% over the last week, with a monthly amount drifted -12.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $48. On March 14, 2024, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $35 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $30 on January 18, 2024. Piper Sandler initiated its recommendation with a Overweight and recommended $37 as its price target on January 16, 2024. RBC Capital Mkts started tracking with a Outperform rating for this stock on October 30, 2023, and assigned it a price target of $25.
NewAmsterdam Pharma Company NV experienced fluctuations in its stock price throughout the past year between $15.19 and $27.29. Currently, Wall Street analysts expect the stock to reach $41.5 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $19.71 at the most recent close of the market. An investor can expect a potential return of 110.55% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.96%, Pretax Profit Margin comes in at -5.35%, and Net Profit Margin reading is -5.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.39 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.57 points at the first support level, and at 17.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.31, and for the 2nd resistance point, it is at 20.91.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NewAmsterdam Pharma Company NV [NASDAQ:NAMS] is 10.61. As well, the Quick Ratio is 10.61, while the Cash Ratio is 7.22.
Transactions by insiders
Recent insider trading involved Douglas F Kling, Affiliate, that happened on Jan 27 ’25 when 0.5 million shares were purchased. Affiliate, Mayur Somalya completed a deal on Jan 27 ’25 to buy 0.2 million shares. Meanwhile, Affiliate NAP PoolCo B.V. bought 1.4 million shares on Jan 10 ’25.
